By inhibiting PAR2-mediated intracellular calcium mobilization and ERK/NF-κB signaling, PCG alleviates skin inflammation and pruritus, highlighting its potential as a therapeutic candidate for atopic dermatitis. Here, F2RL1 is linked to atopic eczema.